Results 331 to 340 of about 47,434 (363)
Some of the next articles are maybe not open access.
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
Nature, 2021Minimally invasive approaches to detect residual disease after surgery are needed to identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA (ctDNA) holds promise as a biomarker for molecular residual disease and relapse1.
Maurizio Perdicchio +28 more
openaire +5 more sources
Chasing ctDNA in Patients With Sarcoma
American Society of Clinical Oncology Educational Book, 2020Liquid biopsies are new technologies that allow cancer profiling of tumor fragments found in body fluids, such as peripheral blood, collected noninvasively from patients with malignancies. These assays are increasingly valuable in clinical oncology practice as prognostic biomarkers, as guides for therapy selection, for treatment monitoring, and for ...
Tony Dickherber +2 more
openaire +3 more sources
Future Oncology, 2023
The standard-of-care for muscle-invasive bladder cancer is radical surgery with neoadjuvant cisplatin-based chemotherapy. Despite curative intent from these interventions, relapse rates post-surgery remain high, with approximately 50% of patients ...
F. Jackson-Spence +6 more
semanticscholar +1 more source
The standard-of-care for muscle-invasive bladder cancer is radical surgery with neoadjuvant cisplatin-based chemotherapy. Despite curative intent from these interventions, relapse rates post-surgery remain high, with approximately 50% of patients ...
F. Jackson-Spence +6 more
semanticscholar +1 more source
Methods for Measuring ctDNA in Lymphomas
2018Plasma cell-free DNA (cfDNA) is an easily accessible source of tumor DNA that allows accurate profiling of lymphoma patients, representing a complementary source of tumor DNA to tissue biopsy for genotyping. Applications of cfDNA analysis in lymphomas include: (1) identification of tumor mutations in a biopsy-free manner; (2) tracking tumor clonal ...
Rossi, Davide +3 more
openaire +4 more sources
The potential of ctDNA analysis in breast cancer
Critical Reviews in Clinical Laboratory Sciences, 2019Breast cancer is a highly heterogeneous and dynamic disease, exhibiting unique somatic alterations that lead to disease recurrence and resistance. Tumor biopsy and conventional imaging approaches are not able to provide sufficient information regarding the early detection of recurrence and real time monitoring through tracking sensitive or resistance ...
Eleni Tzanikou, Evi Lianidou
openaire +3 more sources
ctDNA als Prognosemarker beim DLBCL [PDF]
Im Fokus Onkologie, 2019 Zirkulierende Tumor-DNA (ctDNA) wird derzeit immer wieder als prognostischer Marker diskutiert. Gerade beim diffusen groszelligen B-Zell-Lymphom (DLBCL) ware ein solcher von grosem Wert, da die Behandlungsergebnisse immer noch schwer vorherzusagen sind.
Stefanie Kreutmair +2 more
openaire +1 more source
Technical and biological constraints on ctDNA-based genotyping
Trends in Cancer, 2021Circulating tumor DNA (ctDNA) enables real-time genomic profiling of cancer without the need for tissue biopsy. ctDNA-based technology is seeing rapid uptake in clinical practice due to the potential to inform patient management from diagnosis to advanced disease. In metastatic disease, ctDNA can identify somatic mutations, copy-number variants (CNVs),
Cameron Herberts, Alexander W. Wyatt
openaire +3 more sources
Journal of Clinical Oncology
9 Background: ctDNA-based post-surgical detection of molecular residual disease (MRD) is known to be predictive of a high risk of recurrence. Here, we report the first results of BESPOKE CRC, a multicenter, prospective, observational study evaluating the
P. Kasi +19 more
semanticscholar +1 more source
9 Background: ctDNA-based post-surgical detection of molecular residual disease (MRD) is known to be predictive of a high risk of recurrence. Here, we report the first results of BESPOKE CRC, a multicenter, prospective, observational study evaluating the
P. Kasi +19 more
semanticscholar +1 more source